Results 281 to 290 of about 499,883 (421)
ABSTRACT Background Etrasimod is an oral, once‐daily (q.d.), selective sphingosine 1‐phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO).
Anita Afzali+12 more
wiley +1 more source
Winnie Mice: A Chronic and Progressive Model of Ulcerative Colitis. [PDF]
Chieppa M, De Santis S, Verna G.
europepmc +1 more source
Observations on the absorption of oral betamethasone 17-valerate and its therapeutic value in ulcerative colitis. [PDF]
M. Friedman+5 more
openalex +1 more source
The Role of Intestinal Fungi in the Pathogenesis and Treatment of Ulcerative Colitis. [PDF]
Zhang Y, Wang L, Peng L.
europepmc +1 more source
Studies of intestinal fermentation in ulcerative colitis. [PDF]
R. D. Montgomery+5 more
openalex +1 more source
ABSTRACT Background The treatment landscape for active ulcerative colitis is rapidly evolving and current real‐world evidence on response to advanced therapy is limited. This study aimed to determine indicators of inadequate therapeutic response among patients with ulcerative colitis in Germany initiating advanced therapy.
Axel Dignass+10 more
wiley +1 more source
Highland Barley Improves DSS-Induced Ulcerative Colitis in C57BL/6J Mice. [PDF]
Liu H+6 more
europepmc +1 more source
Phenindione-induced Haemorrhagic Ulcerative Colitis [PDF]
A. R. Tanser, E. C. B. Keat
openalex +1 more source
ABSTRACT Background The Montreal classification has been widely used in Crohn's disease since 2005 to categorize patients by the age of onset (A), disease location (L), behavior (B), and upper gastrointestinal tract and perianal involvement. With evolving management paradigms in Crohn's disease, we aimed to assess the performance of gastroenterologists
Offir Ukashi+44 more
wiley +1 more source
In which patients with ulcerative colitis would filgotinib be effective? [PDF]
Park J.
europepmc +1 more source